BIIE-0246

Last updated
BIIE-0246
BIIE-0246 structure.png
Clinical data
Other namesBIIE-0246
Identifiers
  • N-[(1S)-4-[(Aminoiminomethyl)amino]-1-[([2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]amino)carbonyl]butyl]-1-(2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl)cyclopentaneacetamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C49H57N11O6
Molar mass 896.066 g·mol−1
3D model (JSmol)
  • O=C3N(c1ccccc1)N(c2ccccc2)C(=O)N3CCNC(=O)[C@@H](NC(=O)CC4(CCCC4)CC(=O)N8CCN(C7c5c(cccc5)NC(=O)c6ccccc67)CC8)CCC/N=C(\N)N
  • InChI=1S/C49H57N11O6/c50-46(51)53-25-13-22-40(45(64)52-26-27-58-47(65)59(34-14-3-1-4-15-34)60(48(58)66)35-16-5-2-6-17-35)54-41(61)32-49(23-11-12-24-49)33-42(62)56-28-30-57(31-29-56)43-36-18-7-8-19-37(36)44(63)55-39-21-10-9-20-38(39)43/h1-10,14-21,40,43H,11-13,22-33H2,(H,52,64)(H,54,61)(H,55,63)(H4,50,51,53)/t40-,43?/m0/s1 X mark.svgN
  • Key:RSJAXPUYVJKAAA-JPGJPTAESA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

BIIE-0246 is a drug used in scientific research which acts as a potent and selective antagonist for the Neuropeptide Y receptor Y2. [1] It was one of the first non-peptide Y2-selective antagonists developed, and remains among the most widely used tools for studying this receptor. It has been used to demonstrate a role for the Y2 subtype as a presynaptic autoreceptor limiting further neuropeptide Y release, [2] [3] as well as modulating dopamine [4] and acetylcholine release. [5] It has also been shown to produce several behavioural effects in animals, including reducing alcohol consumption in addicted rats [6] [7] and anxiolytic effects, [8] although while selective Y2 agonists are expected to be useful as anorectics, [9] [10] BIIE-0246 did not appear to increase appetite when administered alone. [11]

References

  1. ↑ Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K (November 1999). "BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist". European Journal of Pharmacology. 384 (2–3): R3–5. doi:10.1016/S0014-2999(99)00650-0. PMID   10611450.
  2. ↑ King PJ, Williams G, Doods H, Widdowson PS (May 2000). "Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release". European Journal of Pharmacology. 396 (1): R1–3. doi:10.1016/S0014-2999(00)00230-2. PMID   10822055.
  3. ↑ Malmström RE, Lundberg JO, Weitzberg E (March 2002). "Autoinhibitory function of the sympathetic prejunctional neuropeptide Y Y(2) receptor evidenced by BIIE0246". European Journal of Pharmacology. 439 (1–3): 113–9. doi:10.1016/S0014-2999(02)01371-7. PMID   11937100.
  4. ↑ Adewale AS, Macarthur H, Westfall TC (May 2007). "Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors". Neuropharmacology. 52 (6): 1396–402. doi:10.1016/j.neuropharm.2007.01.018. PMID   17382974.
  5. ↑ Herring N, Lokale MN, Danson EJ, Heaton DA, Paterson DJ (March 2008). "Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway". Journal of Molecular and Cellular Cardiology. 44 (3): 477–85. doi:10.1016/j.yjmcc.2007.10.001. PMID   17996892.
  6. ↑ Thorsell A, Rimondini R, Heilig M (October 2002). "Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats". Neuroscience Letters. 332 (1): 1–4. doi: 10.1016/S0304-3940(02)00904-7 . PMID   12377370.
  7. ↑ Rimondini R, Thorsell A, Heilig M (February 2005). "Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence". Neuroscience Letters. 375 (2): 129–33. doi:10.1016/j.neulet.2004.10.084. PMID   15670655.
  8. ↑ Bacchi F, Mathé AA, Jiménez P, Stasi L, Arban R, Gerrard P, Caberlotto L (December 2006). "Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze". Peptides. 27 (12): 3202–7. doi:10.1016/j.peptides.2006.07.020. PMID   16959374.
  9. ↑ Félétou M, Levens NR (October 2005). "Neuropeptide Y2 receptors as drug targets for the central regulation of body weight". Current Opinion in Investigational Drugs. 6 (10): 1002–11. PMID   16259221.
  10. ↑ Parker SL, Balasubramaniam A (February 2008). "Neuropeptide Y Y2 receptor in health and disease". British Journal of Pharmacology . 153 (3): 420–31. doi:10.1038/sj.bjp.0707445. PMC   2241788 . PMID   17828288.
  11. ↑ Scott V, Kimura N, Stark JA, Luckman SM (July 2005). "Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour". Journal of Neuroendocrinology. 17 (7): 452–7. doi:10.1111/j.1365-2826.2005.01330.x. PMID   15946163.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.